Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Corporate / Unallocated Reconciling Item by Year
Corporate / Unallocated Reconciling Item — Acquisition-related costs pretax impact ($M) ($M)
Pfizer Corporate / Unallocated Reconciling Item: -$1,285M in FY2025, down 33.7% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Note 17 — Segment Reporting (ASU 2023-07 Significant Segment Expenses).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Corporate / Unallocated Reconciling Item — Acquisition-related costs pretax impact ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1,285 | -33.7% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | -1,938 | +3.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | -1,874 | +125.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | -832 | +498.6% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | -139 | +41.8% | Form 10-K (filed 2024-02-22) ↗ |
| FY2020 | Dec 31, 2020 | -98 | -47.0% | Form 10-K (filed 2023-02-23) ↗ |
| FY2019 | Dec 31, 2019 | -185 | – | Form 10-K (filed 2022-02-24) ↗ |
Cite this data
StockData. (2026). Pfizer Corporate / Unallocated Reconciling Item ($M), annual FY2019–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/seg-ebt-recon-acq
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.